Cited by 404Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)

Open access

Kirchhof, Paulus, Ammentorp, Bettina, Darius, Harald, De Caterina, Raffaele, Le Heuzey, Jean-Yves, Schilling, Richard John, Schmitt, Josef, Zamorano, Jose Luis·2014·EP Europace

DOI 10.1093/europace/eut263PMC PMC3864758

Open this paper in CoChat — free account Open PDF

Abstract

AIMS: We sought to describe the management of patients with atrial fibrillation (AF) in Europe after the release of the 2010 AF Guidelines of the European Society of Cardiology. METHODS AND RESULTS: The PREFER in AF registry enrolled consecutive patients with AF from January 2012 to January 2013 in 461 centres in seven European countries. Seven thousand two hundred and forty-three evaluable patients were enrolled, aged 71.5 ± 11 years, 60.1% male, CHA2DS2VASc score 3.4 ± 1.8 (mean ± standard deviation). Thirty per cent patients had paroxysmal, 24.0% had persistent, 7.2% had long-standing persistent, and 38.8% had permanent AF. Oral anticoagulation was used in the majority of patients: 4799 patients (66.3%) received a vitamin K antagonist (VKA) as mono-therapy, 720 patients a combination of VKA and antiplatelet agents (9.9%), 442 patients (6.1%) a new oral anticoagulant drugs (NOAC). Antiplatelet agents alone were given to 808 patients (11.2%), no antithrombotic therapy to 474 patients (6.5%). Of 7034 evaluable patients, 5530 (78.6%) patients were adequately rate controlled (mean heart rate 60-100 bpm). Half of the patients (50.7%) received rhythm control therapy by electrical cardioversion (18.1%), pharmacological cardioversion (19.5%), antiarrhythmic drugs (amiodarone 24.1%, flecainide or propafenone 13.5%, sotalol 5.5%, dronedarone 4.0%), and catheter ablation (5.0%). CONCLUSION: The management of AF patients in 2012 has adapted to recent evidence and guideline recommendations. Oral anticoagulant therapy with VKA (majority) or NOACs is given to over 80% of eligible patients, including those at risk for bleeding. Rate is often adequately controlled, and rhythm control therapy is widely used.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/europace/eut263

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study
Lloyd-Jones, D. M., Wang, T. J., Leip, E. P., Larson, M. G., Levy, D., Vasan, R. S., D’Agostino, R. B., Massaro, J. M., Beiser, A., Wolf, P. A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000140263.20897.42 · Cited by 2,041
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study
Heeringa, J., van der Kuip, D. A. M., Hofman, A., Kors, J. A., van Herpen, G., Stricker, B. H. C., Stijnen, T., Lip, G. Y. H., & Witteman, J. C. M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi825 · Cited by 1,939
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · EP Europace · doi:10.1093/europace/euq350 · Cited by 1,764
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
Olesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.-M. S., Gislason, G. H., et al. (2011) · BMJ · doi:10.1136/bmj.d124 · Cited by 1,428
Lenient versus strict rate control in patients with atrial fibrillation
Van Gelder, I. C., Groenveld, H. F., Crijns, H. J. G. M., Tuininga, Y. S., Tijssen, J. G. P., Alings, A. M., Hillege, H. L., Bergsma-Kadijk, J. A., Cornel, J. H., Kamp, O., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001337 · Cited by 1,033
Atrial fibrillation management: a prospective survey in ESC Member Countries
Nieuwlaat, R., Capucci, A., Camm, A. J., Olsson, S. B., Andresen, D., Davies, D. W., Cobbe, S. M., BREITHARDT, G. E., Heuzey, J. L., Prins, M. H., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi505 · Cited by 825
Progression From Paroxysmal to Persistent Atrial Fibrillation
de Vos, C. B., Pisters, R., Nieuwlaat, R., Prins, M. H., Tieleman, R. G., Coelen, R. J. S., Heijkant, A. C. V. D., Allessie, M. A., & Crijns, H. J. G. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.11.040 · Cited by 720
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
Kakkar, A. K., Mueller, I., Bassand, J., Fitzmaurice, D. A., Goldhaber, S. Z., Goto, S., Haas, S. K., Hacke, W., Lip, G. Y. H., Mantovani, L. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063479 · Cited by 449
The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management
Nabauer, M., Gerth, A., Limbourg, T., Schneider, S., Oeff, M., Kirchhof, P., Goette, A., Lewalter, T., Ravens, U., Meinertz, T., et al. (2008) · Europace · doi:10.1093/europace/eun369 · Cited by 427

Flagged first, then by citations

Show all 24 references

Research works printed but not linked: 1

Lip, 2013, EUR Observational research programme: atrial fibrillation general registry pilot phase, Eur H J, 34, 794

Sorted by citations

Items 101–200 of 404

Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study
Ajabnoor, A. M., Zghebi, S. S., Parisi, R., Ashcroft, D. M., Rutter, M. K., Doran, T., Carr, M., Mamas, M. A., & Kontopantelis, E. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004003 · Cited by 27
Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
da Silva, R. M. F. L. (2014) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152571201141201091848 · Cited by 27
Análisis coste-efectividad de apixabán frente a acenocumarol en la prevención del ictus en pacientes con fibrilación auricular no valvular en España
Barón‐Esquivias, G., Escolar, G., Zamorano, J. L., Nicolás, L. B., Fontcuberta, C. C., de Salas-Cansado, M., Rubio-Rodríguez, D., & Rubio‐Terres, C. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.08.010 · Cited by 27
The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey
On behalf of the BALKAN-AF Investigators, Potpara, T., Trendafilova, E., Dan, G., Goda, A., Kušljugić, Z., Manola, Š., Musić, L., Gjini, V., Pojskić, B., et al. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0589-5 · Cited by 26
Benefits of early rhythm control of atrial fibrillation
Eckardt, L., Wolfes, J., & Frommeyer, G. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.04.001 · Cited by 27
Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry
on behalf of the AFNET registry investigators, Hæusler, K. G., Gerth, A., Limbourg, T., Tebbe, U., Oeff, M., Wegscheider, K., Treszl, A., Ravens, U., Meinertz, T., et al. (2015) · BMC Neurology · doi:10.1186/s12883-015-0371-8 · Cited by 26
Underuse of Oral Anticoagulants and Inappropriate Prescription of Antiplatelet Therapy in Older Inpatients with Atrial Fibrillation
Averlant, L., Ficheur, G., Ferret, L., Boulé, S., Puisieux, F. L., Luyckx, M., Soula, J., Georges, A., Beuscart, R., Chazard, E., et al. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0477-3 · Cited by 25
Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain
Barón‐Esquivias, G., Escolar, G., Zamorano, J. L., Nicolás, L. B., Fontcuberta, C. C., de Salas-Cansado, M., Rubio-Rodríguez, D., & Rubio‐Terres, C. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.08.010 · Cited by 24
Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?
Esteve‐Pastor, M. A., García-Fernández, A., Macías, M. J., Sogorb, F., Valdés, M., Roldán, V., Muñiz, J., Badimón, L., Roldán, I., Bertoméu, V., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0471 · Cited by 24
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy
Caterina, R. D., Brüggenjürgen, B., Darius, H., Köhler, S., Lucerna, M., Pecen, L., Renda, G., SCHILLING, R. J., Schliephacke, T., Zamorano, J. L., et al. (2017) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2017.04.007 · Cited by 24
Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF
Hanon, O., Vidal, J., Heuzey, J. L., Kirchhof, P. F., Caterina, R. D., Schmitt, J., Laeis, P., Mannucci, P. M., & Marcucci, M. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.01.046 · Cited by 24
Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program
McIntyre, W. F., Conen, D., Olshansky, B., Halperin, J. L., Hayek, E. R., Huisman, M. V., Lip, G. Y. H., Lu, S., & Healey, J. S. (2018) · Clinical Cardiology · doi:10.1002/clc.22936 · Cited by 24
Current Antiarrhythmic Therapy for Nonvalvular Atrial Fibrillation in Spain. Data From the FANTASIIA Registry
Rabadán, I. R., Sánchez, M. A., Marín, F. R., Simón, M. A. Q., Siles, J. C., Peinado, R., Bertoméu, V., Cequier, A. R., Badimón, L., & Muñiz, J. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.03.004 · Cited by 23
The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998–2014
Hayward, C., Patel, H. C., Patel, K., Mario, C. D., Lyon, A. R., Ahsan, S., & Rowland, E. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv048 · Cited by 23
Atrial fibrillation and use of antithrombotic medications in older people: A population-based study
Ding, M., Fratiglioni, L., Johnell, K., Fastbom, J., Ljungdahl, M., & Qiu, C. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.012 · Cited by 23
Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes
Potpara, T., Lane, D. A., & Lip, G. Y. H. (2015) · EP Europace · doi:10.1093/europace/euv041 · Cited by 23
Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study
Douros, A., Cui, Y. J., Platt, R. W., Filion, K. B., Sebastiani, G., & Renoux, C. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.03.024 · Cited by 22
The Cumulative Incidence of Stroke, Myocardial infarction, Heart Failure and Sudden Cardiac Death in Patients with Atrial Fibrillation
Naser, N., Kulić, M., Dilić, M., Džubur, A., Durak-Nalbantić, A., Pepic, E., Smajić, E., & Kušljugić, Z. (2017) · Medical Archives · doi:10.5455/medarh.2017.71.316-319 · Cited by 23
Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation ― The Fushimi AF Registry ―
Masunaga, N., Abe, M., Ogawa, H., Aono, Y., Ikeda, S., Doi, K., An, Y., Ishii, M., Iguchi, M., Esato, M., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0872 · Cited by 22
Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Catheter Ablation or Antiarrhythmic Drug Therapy: A Systematic Review and Meta-analysis
Allan, K. S., Aves, T., Henry, S., Banfield, L. E., Victor, J. C., Dorian, P., Healey, J. S., Andrade, J. G., Carroll, S. L., & McGillion, M. H. (2020) · CJC Open · doi:10.1016/j.cjco.2020.03.013 · Cited by 22
Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective
Lorenzoni, V., Pirri, S., & Turchetti, G. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01002-z · Cited by 21
S2k-Leitlinie: Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke (TIA) – Teil 1 und Teil 2
Hamann, G. F., Sander, D., Grau, A., & Röther, J. (2022) · DGNeurologie · doi:10.1007/s42451-022-00461-8 · Cited by 21
Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF)
Fox, K. A. A., Accetta, G., Pieper, K. S., Bassand, J., Camm, A. J., Fitzmaurice, D. A., Kayani, G., Kakkar, A. K., & for the GARFIELD-AF Investigators (2017) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcx030 · Cited by 21
Effects of oral anticoagulant therapy in older medical in-patients with atrial fibrillation: a prospective cohort observational study
Bo, M., Puma, F. L., Martini, M. B., Falcone, Y., Iacovino, M., Grisoglio, E., Menditto, E., Fonte, G., Brunetti, E., Isaia, G. C., et al. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0569-7 · Cited by 21
Effects of Oral Anticoagulant Therapy in Medical Inpatients ≥65 Years With Atrial Fibrillation
Bo, M., Sciarrillo, I., Puma, F. L., Martini, M. B., Falcone, Y., Iacovino, M., Grisoglio, E., Menditto, E., Fonte, G., Brunetti, E., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.11.032 · Cited by 20
Adherence to the ABC (Atrial fibrillation Better Care) pathway in the Balkan region: the BALKAN-AF survey
Kozieł, M., Simovic, S. M., Pavlović, N., Kocijančić, A., Paparisto, V., Musić, L., Trendafilova, E., Dan, A. R., Kušljugić, Z., Dan, G., et al. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15146 · Cited by 20
Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey
Sabouret, P. F., Bricard, M., Hermann, M.-A., Cotté, F.-E., Depret-Bixio, L., & Rushton-Smith, S. K. (2015) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2015.05.005 · Cited by 20
Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network
Lavalle, C., Lullo, L. D., Bellasi, A., Ronco, C., Radicchia, S., Bàrbera, V., Galardo, G., Piro, A., Magnocavallo, M., Straito, M., et al. (2020) · Cardiorenal Medicine · doi:10.1159/000507046 · Cited by 20
EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION
Sp, G., Панченко, Е. П., Станиславовна, К. Е., Laiovich, L. I., Maykov, E. B., Mironov, N. Y., & Shakhmatova, O. O. (2019) · Eurasian heart journal · doi:10.38109/2225-1685-2019-4-4-85 · Cited by 21
Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry
Cools, F. J. S., Wollaert, B., Vervoort, G., Verstraete, S., Voet, J., Hermans, K., Heyse, A., Wolf, A. D., Hollanders, G., Boussy, T., et al. (2018) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2018.1494089 · Cited by 20
New Oral Anticoagulants in Nonvalvular Atrial Fibrillation
Fatima, U., Kulkarni, A., Stapleton, D. D., & Kaluski, E. (2016) · Clinical Cardiology · doi:10.1002/clc.22582 · Cited by 19
Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study
Melgaard, L., Overvad, T. F., Jensen, M., Lip, G. Y. H., Larsen, T. B., & Nielsen, P. B. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa008 · Cited by 19
Tratamiento antiarrítmico actual de la fibrilación auricular no valvular en España. Datos del Registro FANTASIIA
Rabadán, I. R., Sánchez, M. A., Marín, F. R., Simón, M. A. Q., Siles, J. C., Peinado, R., Bertoméu, V., Cequier, A. R., Badimón, L., & Muñiz, J. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.03.007 · Cited by 18
Situación del tratamiento anticoagulante oral en pacientes con fibrilación auricular no valvular en España. Estudio REACT-AF
de Andrés-Nogales, F., Oyagüez, I., Nicolás, L. B., Fontcuberta, C. C., & Soto-Álvarez, J. (2014) · Revista Clínica Española · doi:10.1016/j.rce.2014.08.008 · Cited by 18
Efficacy and Safety of Oral Anticoagulants Versus Aspirin for Patients With Atrial Fibrillation
Zhang, J., Chen, K., & Zhang, S. (2015) · Medicine · doi:10.1097/md.0000000000000409 · Cited by 18
Cardioversion in Non-Valvular Atrial Fibrillation
Klein, H. H., & Trappe, H. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0856 · Cited by 18
Comparing the clinical outcomes in patients with atrial fibrillation receiving dual antiplatelet therapy and patients receiving an addition of an anticoagulant after coronary stent implantation
Chaudhary, N., Bundhun, P. K., & He, Y. (2016) · Medicine · doi:10.1097/md.0000000000005581 · Cited by 18
Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation
Hesselkilde, E. M., Carstensen, H., Haugaard, M. M., Carlson, J., Pehrson, S. M., Jespersen, T., Buhl, R., & Platonov, P. G. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0720-1 · Cited by 18
Role of the autonomic nervous system in atrial fibrillation pathogenesis
Попова, Е., Bogova, O. T., Puzin, S. N., & Фисенко, В. П. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-3663 · Cited by 17
Inappropriate Underdosing of Direct Oral Anticoagulants in Atrial Fibrillation Patients: Results from the START2-AF Registry
Poli, D., Antonucci, E., Ageno, W., Berteotti, M., Falanga, A., Pengo, V., Chiarugi, P., Cosmi, B., Paparo, C., Chistolini, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072009 · Cited by 17
Atrial Fibrillation in the Elderly: A Review
Hakim, F. A., & Shen, W.-K. (2014) · Future Cardiology · doi:10.2217/fca.14.32 · Cited by 19
Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries
Ogawa, H., Senoo, K., An, Y., Shantsila, A., Shantsila, E., Lane, D. A., Wolff, A., Akao, M., & Lip, G. Y. H. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.022 · Cited by 17
Esmolol Compared with Amiodarone in the Treatment of Recent-Onset Atrial Fibrillation (RAF): An Emergency Medicine External Validity Study
Milojévic, K., Beltramini, A., Nagash, M., Muret, A., Richard, O., & Lambert, Y. (2019) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2018.12.010 · Cited by 17
Comparison between Amulet and Watchman left atrial appendage closure devices: A real-world, single center experience
Saad, M. F., Risha, O., Sano, M., Fink, T., Heeger, C.-H. H., Vogler, J., Sciacca, V., Eitel, C., Stiermaier, T., Joost, A., et al. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100893 · Cited by 17
Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries
Rohla, M., Pecen, L., Cemin, R., Patti, G., Siller-Matula, J. M., Schnabel, R. B., Huber, K., Kirchhof, P. F., & Caterina, R. D. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006852 · Cited by 18
Individualized approaches to thromboprophylaxis in atrial fibrillation
Ziff, O. J., & Camm, A. J. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.10.021 · Cited by 18
Patients with Atrial Fibrillation in Clinical Practice: Comorbidity, Drug Treatment and Outcomes (Data from RECVASA Registries)
Loukianov, М. М., Andreenko, Е. Y., Martsevich, S. Y., Yаkushin, S. S., Vorobyev, A. N., Pereverzeva, K. G., Zagrebelnyy, A. V., Okshina, Е. Y., Yakusevich, V. V., Yakusevich, V. V., et al. (2020) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2020-12-01 · Cited by 16
Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term
Breithardt, G., & Baumgartner, H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv193 · Cited by 16
A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark
Vestergaard, A. S., & Ehlers, L. H. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0281-z · Cited by 15
Prevalência da anticoagulação oral em doentes com fibrilhação auricular em Portugal: revisão sistemática e meta‐análise de estudos observacionais
Caldeira, D., Barra, M., David, C., Costa, J. N., Ferreira, J. J., & Pinto, F. J. (2014) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2014.02.014 · Cited by 15
Preclinical assessment of a modified Occlutech left atrial appendage closure device in a porcine model
Reinthaler, M., Großhauser, J., Schmidt, T., Unger, J. K., Morgan, R., Zimmermann, F., Hartung, J., Seppelt, C., Meteva, D., Haider, W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82359-1 · Cited by 15
Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: Insights from the RealiseAF Taiwanese cohort
Wang, K.-L., Wu, C., Huang, C., Wu, T.-C., Naditch‐Brûlé, L., Steg, P. G., Lin, S., & Chiang, C. (2014) · Journal of Cardiology · doi:10.1016/j.jjcc.2014.01.010 · Cited by 15
Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting
Pandya, E., Anderson, E. A., Chow, C. K., Wang, Y., & Bajorek, B. V. (2017) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617744926 · Cited by 15
Comparing Management and Outcomes in Men and Women With Nonvalvular Atrial Fibrillation
Arnson, Y., Hoshen, M., Senderey, A. B., Reges, O., Balicer, R. D., Leibowitz, M., Tsadok, M. A., & Haim, M. (2018) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2018.01.014 · Cited by 15
A comprehensive insight of novel antioxidant therapies for atrial fibrillation management.
Orenes‐Piñero, E., Valdés, M., Lip, G. Y. H., & Marín, F. R. (2015) · PubMed · doi:10.3109/03602532.2015.1077858 · Cited by 14
Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies
Patti, G., Pecen, L., Manu, M. C., Huber, K., Rohla, M., Renda, G., Siller-Matula, J. M., Ricci, F., Kirchhof, P. F., & Caterina, R. D. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.06.010 · Cited by 14
Carga y coste del mal control de la anticoagulación con antagonistas de la vitamina K en pacientes con fibrilación auricular no valvular en España
Barrios, V., Cinza‐Sanjurjo, S., Gavín, O., Egocheaga, I., Burgos-Pol, R., Soto, J., Polanco, C., Suárez, J., & Casado, M. Á. (2020) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.06.009 · Cited by 14
Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA : Results from the National Tunisian Registry of Atrial Fibrillation ( NATURE‐AF )
Ouali, S., Halima, A. B., Chabrak, S., Chettaoui, R., Halima, M. B., Haggui, A., Krichane, S., Larbi, N., Marrakchi, S., Charfeddine, S., et al. (2021) · Clinical Cardiology · doi:10.1002/clc.23558 · Cited by 14
Sex-Differences in Atrial Fibrillation Patients: Bias or Proper Management?
Israeli, A., Gal, D., Younis, A., Ehrenberg, S., Rozner, E., Turgeman, Y., Naami, E., Naami, R., & Koren, O. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s366285 · Cited by 14
Perindopril for the prevention of atrial fibrillation recurrence after radiofrequency catheter ablation: One-year experience
Wang, Q., Shang, Y., Wang, Z., Zhou, D., Dong, F., Qiu, Y., Li, H., & Zheng, L. (2016) · Heart Rhythm · doi:10.1016/j.hrthm.2016.06.039 · Cited by 14
Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS
Camm, A. J., Amarenco, P., Haas, S. K., Hess, S., Kirchhof, P. F., Lambelet, M., Bach, M., & Turpie, A. G. G. (2018) · EP Europace · doi:10.1093/europace/euy160 · Cited by 14
Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF
Verheugt, F. W. A., Ambrosio, G., Atar, D., Bassand, J., Camm, A. J., Costabel, J. P., Fitzmaurice, D. A., Illingworth, L., Goldhaber, S. Z., Goto, S., et al. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.06.008 · Cited by 15
Quality indicators in the management of elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry
Guo, Y., Kotalczyk, A., Imberti, J. F., Wang, Y., Lip, G. Y. H., & ChiOTEAF Registry Investigators (2021) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcab057 · Cited by 14
Design and deployment of the STEEER-AF trial to evaluate and improve guideline adherence: a cluster-randomized trial by the European Society of Cardiology and European Heart Rhythm Association
Sterlinski, M. M., Bunting, K. V., Boriani, G., Bovéda, S., Guasch, E., Mont, L., Rajappan, K., Sommer, P., Mehta, S. P., Sun, Y., et al. (2024) · EP Europace · doi:10.1093/europace/euae178 · Cited by 13
More obvious association between short-term ambient nitrogen dioxide and atrial fibrillation outpatient visits in cool seasons: A hospital-based study in northwestern China
Zhou, C., Hu, Y.-G., Fan, Y., Wu, N., Yao, C., Liu, X., Zhou, Y., Xiao, H., Tang, E., Li, D., et al. (2022) · Environmental Research · doi:10.1016/j.envres.2022.113220 · Cited by 13
The Risk of Hospital Admission Due to Traumatic Brain Injury Is Increased in Older Persons With Severe Functional Limitations
Büchele, G., Rapp, K., König, H., Jaensch, A., Rothenbacher, D., Becker, C., & Benzinger, P. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.02.032 · Cited by 13
Of hammers and screws: renin-angiotensin-aldosterone system inhibition to prevent atrial fibrillation in patients with hypertension
Kirchhof, P. F., & Fabritz, L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu068 · Cited by 12
The Guideline-Policy Gap in Direct-Acting Oral Anticoagulants Usage in Atrial Fibrillation: Evidence, Practice, and Public Policy Considerations
Wan, D., Healey, J. S., & Simpson, C. S. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.07.476 · Cited by 12
The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
Beyer‐Westendorf, J., Fay, M., & Amara, W. (2021) · TH Open · doi:10.1055/s-0041-1731777 · Cited by 12
Effectiveness and safety of drugs used for stroke prevention in a cohort of non‐valvular atrial fibrillation patients from a primary care electronic database
Giner‐Soriano, M., Roso‐Llorach, A., Urgell, C. V., Cervelló, X. C., Capellà, D., González, I. F., Elorza, J. M., Casajuana‐Closas, M., Troncoso‐Mariño, A., Diogène, E., et al. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4137 · Cited by 12
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks
Singh, M., Bhatt, D. L., Stone, G. W., Rihal, C. S., Gersh, B. J., Lennon, R. J., Narula, J., & Fuster, V. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.06.013 · Cited by 11
Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
Rubio‐Terres, C., de Codes, R. G., Rubio-Rodríguez, D., Evers, T., & Grau, S. (2016) · Journal of health economics and outcomes research · doi:10.36469/9823 · Cited by 12
Rhythm versus rate control in patients with newly diagnosed atrial fibrillation – Observations from the GARFIELD-AF registry
Pope, M. K., Hall, T. S., Virdone, S., Atar, D., Camm, A. J., Pieper, K. S., Janský, P., Haas, S. K., Goto, S., Панченко, Е. П., et al. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101302 · Cited by 11
Multidisciplinary Approach in Atrial Fibrillation: As Good as Gold
Lucà, F., Abrignani, M. G., Oliva, F. G., Canale, M. L., Parrini, I., Murrone, A., Rao, C. M., Nesti, M., Cornara, S., Matteo, I. D., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164621 · Cited by 17
Do CHA2DS2VASc and HAS‐BLED scores influence ‘real‐world’ anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre
Łopatowska, P., Tomaszuk−Kazberuk, A., Młodawska, E., Bachórzewska-Gajewska, H., Małyszko, J., Dobrzycki, S., & Musial, W. J. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3878 · Cited by 11
Does Left Atrial Appendage Amputation During Routine Cardiac Surgery Reduce Future Atrial Fibrillation and Stroke?
Domínguez, H., Madsen, C. V., Westh, O. N. H., Pallesen, P. A., Carranza, C. L., Irmukhamedov, A., & Park-Hansen, J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1033-4 · Cited by 11
Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study
Melgaard, L., Jensen, M., Overvad, T. F., Larsen, T. B., Lip, G. Y. H., & Nielsen, P. B. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13589 · Cited by 11
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention
Olivier, C. B., Fan, J., Askari, M., Mahaffey, K. W., Heidenreich, P. A., Perino, A. C., Leef, G. C., Ho, P. M., Harrington, R. A., & Turakhia, M. P. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.118.007604 · Cited by 11
Echocardiography guided management of atrial fibrillation
Balík, M., Vignon, P., Chew, M. S., Tavazzi, G., Mayo, P. H., Douflé, G., Aron, J., Hastings, J., Cholley, B., Jiroutková, K., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08112-8 · Cited by 10
Changes in Oral Anticoagulant Treatment Rates in Atrial Fibrillation before and after the Introduction of Direct Oral Anticoagulants
Shah, R. U., Rupp, A. B., Mowery, D. L., Zhang, M., Stoddard, G., Deshmukh, V. G., Bray, B. E., Hess, R., & Rondina, M. T. (2016) · Neuroepidemiology · doi:10.1159/000455012 · Cited by 10
Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study
Balík, M., Waldauf, P., Malý, M., Matoušek, V., Brožek, T., Rulíšek, J., Pořízka, M., Šachl, R., Otáhal, M., Brestovansky, P., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031678 · Cited by 10
Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over
Decaestecker, M. C., Ferret, L., Decaestecker, K., Gautier, S., Verdun, S., & Tsogli, E. S. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00883-1 · Cited by 10
Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study
Lópes, R. D., de Paola, Â. A. V., Filho, A. M. L., Consolim‐Colombo, F. M., Andrade, J., Mattos, L. A., Bernardez‐Pereira, S., Berwanger, O. B., & Figueiredo, M. J. D. O. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.03.001 · Cited by 10
The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
Zheng, H., Ouyang, S., Zhao, Y., Lü, K., Luo, S., & Xiao, H. (2017) · International Journal of General Medicine · doi:10.2147/ijgm.s128047 · Cited by 10
Epidemiology and long-term prognosis of atrial fibrillation in rural African patients
Mandi, D. G., Bamouni, J., Naïbé, D. T., Yaméogo, R. A., Kabore, E., Kambiré, Y., Kologo, K. J., Millogo, G. R. C., Yaméogo, N. V., Tall-Thiam, A., et al. (2019) · The Egyptian Heart Journal · doi:10.1186/s43044-019-0005-3 · Cited by 10
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis
Akao, M., Yasuda, S., Kaikita, K., Ako, J., Matoba, T., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., Hirayama, A., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.02.021 · Cited by 10
Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
Botto, G. L., Ameri, P., & Caterina, R. D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132866 · Cited by 11
Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives
Blann, A. D., Boriani, G., & Lip, G. Y. H. (2016) · EP Europace · doi:10.1093/europace/euw211 · Cited by 10
Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
Ioannou, A., Tsappa, I., Metaxa, S., & Missouris, C. G. (2017) · Patient Related Outcome Measures · doi:10.2147/prom.s117549 · Cited by 10
Prevalence and risk factors of left atrial thrombus in patients with atrial fibrillation and lower class (IIa) recommendation to anticoagulants
Uziębło‐Życzkowska, B., Krzesiński, P., Jurek, A., Budnik, M., Gorczyca−Michta, I., Kapłon‐Cieślicka, A., Kiliszek, M., Wójcik, A., Gawalko, M. M., Jelonek, O. E., et al. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-151 · Cited by 10
Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review
Chang, K., Arbit, B., & Hsu, J. C. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.119 · Cited by 9
Echocardiography predictors of sustained sinus rhythm after cardioversion of supraventricular arrhythmia in patients with septic shock
Balík, M., Waldauf, P., Malý, M., Brožek, T., Rulíšek, J., Pořízka, M., Šachl, R., Otáhal, M., Brestovansky, P., Svobodová, E., et al. (2024) · Journal of Critical Care · doi:10.1016/j.jcrc.2024.154832 · Cited by 9
Anticoagulation management in non-valvular atrial fibrillation in rural and remote Crete. A single-center study from the region of Sitia
Papakonstantinou, P. Ε., Asimakopoulou, N., Gargeraki, A., Gaitanis, K. S., & Mintzaridis, E. (2016) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2016.05.005 · Cited by 9
A Simple Score to Predict New-Onset Atrial Fibrillation After Ablation of Typical Atrial Flutter
Gu, Z., Jiao, J., Shen, Y., Ding, X., Zhu, C., Li, M., Chen, H., Ju, W., Gu, K., Yang, G., et al. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.02.006 · Cited by 9
Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF study
de Andrés-Nogales, F., Oyagüez, I., Nicolás, L. B., Fontcuberta, C. C., & Soto-Álvarez, J. (2014) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2014.08.003 · Cited by 9
Therapeutic management in ambulatory elderly patients with atrial fibrillation: The S.AGES cohort
Hanon, O., Vidal, J., Pisica–Donose, G., Benattar‐Zibi, L., Bertin, P., Berrut, G., Corruble, E., Dérumeaux, G., Falissard, B., Forette, F., et al. (2015) · The journal of nutrition health & aging · doi:10.1007/s12603-015-0444-9 · Cited by 9
Non Valvular Atrial Fibrillation Related Ischaemic Stroke at the Teaching Hospital of Yalgado Ouédraogo, Burkina Faso
K, M. D. G. S. (2015) · Journal of Vascular Medicine & Surgery · doi:10.4172/2329-6925.1000171 · Cited by 9
Adverse clinical events in Japanese atrial fibrillation patients with and without coronary artery disease—findings from the SAKURA AF Registry
Fukamachi, D., Okumura, Y., Yokoyama, K., Matsumoto, N., Tachibana, E., Kuronuma, K., Oiwa, K., Matsumoto, M., Nishida, T., Kojima, T., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1650014 · Cited by 9
Trends in preadmission oral anticoagulant use and clinical outcome in atrial fibrillation patients admitted with acute stroke in Denmark
Larsen, L. K., Ovesen, C., Frost, L., Damgaard, D., Christensen, H., & Johnsen, S. P. (2019) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcz063 · Cited by 9
Left atrial appendage occlusion for stroke prevention – state of the art as provided in an updated EHRA/EAPCI consensus statement and future perspectives
Skurk, C., & Landmesser, U. (2020) · EuroIntervention · doi:10.4244/eijv15i13a207 · Cited by 9

Authors: Kirchhof, P., Ammentorp, B., Darius, H., De Caterina, R., Le Heuzey, J.-Y., Schilling, R. J., Schmitt, J., & Zamorano, J. L.
Affiliations: University of Münster (DE)
Daiichi Sankyo (Germany) (DE)
Vivantes Klinikum (DE)
St Thomas' Hospital (GB)
Corresponding author: Kirchhof, Paulus
ORCID: Kirchhof, Paulus
Schilling, Richard John
Venue: EP Europace
Publisher: Oxford University Press (OUP)
Published: 2013-10-01
Volume: 16
Issue: 1
Pages: 6-14
ISSN: 1099-5129 (ISSN-L)
1532-2092
DOI: 10.1093/europace/eut263
PMC: PMC3864758
OpenAlex: W1973416160
Cited by: 404
References: 24
Citations by year: 2026: 3 · 2025: 8 · 2024: 16 · 2023: 15 · 2022: 20 · 2021: 31 · 2020: 46 · 2019: 27 · 2018: 36 · 2017: 59 · 2016: 44 · 2015: 56 · 2014: 36 · 2013: 6
FWCI: 32.15
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
Locations: EP Europace (publishedVersion, cc-by-nc)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Funders: Daiichi Sankyo Europe
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: atrial fibrillation, clinical management, oral anticoagulation, vitamin K antagonists, direct oral anticoagulants, antiplatelet therapy, rate control, rhythm control, cardioversion, antiarrhythmic drugs, catheter ablation, guideline adherence, bleeding risk, CHA2DS2-VASc score
MeSH terms: Aged, Anticoagulants, Atrial Fibrillation, Cardiology, Europe, Female, Humans, Male, Practice Patterns, Physicians', Platelet Aggregation Inhibitors, Registries, Thromboembolism, Vitamin K, Comorbidity, Causality, Prevalence, Practice Guidelines as Topic, Guideline Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks